Hayden M. Pagendarm

Hayden M. Pagendarm

Auto-generated profile, based on publicly available information

Hayden M. Pagendarm

Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37232, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2024 in ACS Nano
Verified
Journal Article
Open access
JBJessalyn J. Baljon
Jessalyn J. Baljon
AKAlexander J. Kwiatkowski
Alexander J. Kwiatkowski
HPHayden M. Pagendarm
Hayden M. Pagendarm
PSPayton T. Stone
Payton T. Stone
AKAmrendra Kumar
Amrendra Kumar
JWJohn T. Wilson
John T. Wilson
Immune checkpoint blockade (ICB) has revolutionized cancer treatment and led to complete and durable responses, but only for a minority of patients. Resistance to ICB can largely be attributed to insufficient number and/or function of antitumor CD8+ T cells in the tumor microenvironment. Neoantigen targeted cancer vaccines can activate and expand the antitumor T cell repertoire, but historically, clinical responses have been poor because immunity against peptide antigens is typically weak, resulting in insufficient activation of CD8+ cytotoxic T cells. Herein, we describe a nanoparticle vaccine platform that can overcome these barriers in several ways. First, the vaccine can be reproducibly formulated using a scalable confined impingement jet mixing method to coload a variety of physicochemically diverse peptide antigens and multiple vaccine adjuvants into pH-responsive, vesicular nanoparticles that are monodisperse and less than 100 nm in diameter. Using this approach, we encapsulated synergistically acting adjuvants, cGAMP and monophosphoryl lipid A (MPLA), into the nanocarrier to induce a robust and tailored innate immune response that increased peptide antigen immunogenicity. We found that incorporating both adjuvants into the nanovaccine synergistically enhanced expression of dendritic cell costimulatory markers, pro-inflammatory cytokine secretion, and peptide antigen cross-presentation. Additionally, the nanoparticle delivery increased lymph node accumulation and uptake of peptide antigen by dendritic cells in the draining lymph node. Consequently, nanoparticle codelivery of peptide antigen, cGAMP, and MPLA enhanced the antigen-specific CD8+ T cell response and delayed tumor growth in several mouse models. Finally, the nanoparticle platform improved the efficacy of ICB immunotherapy in a murine colon carcinoma model. This work establishes a versatile nanoparticle vaccine platform for codelivery of peptide neoantigens and synergistic adjuvants to enhance responses to cancer vaccines.

11 June 2025 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
BKBlaise Russel Kimmel
Blaise Russel Kimmel
KAKaran Arora
Karan Arora
NCNeil C. Chada
Neil C. Chada
VBVijaya Bharti
Vijaya Bharti
AKAlexander J. Kwiatkowski
Alexander J. Kwiatkowski
JWJohn T. Wilson
John T. Wilson
The enhancement of antitumour immunity via agonists of the stimulator of interferon genes (STING) pathway is limited by pharmacological barriers. Here we show that the covalent conjugation of a STING agonist to anti-albumin nanobodies via site-selective bioconjugation chemistries prolongs the circulation of the agonist in the blood and increases its accumulation in tumour tissue, stimulating innate immune programmes that increased the infiltration of activated natural killer cells and T cells, which potently inhibited the growth of mouse tumours. The technology is modular, as demonstrated by the recombinant integration of a second nanobody domain targeting programmed death-ligand 1 (PD-L1), which further increased the accumulation of the agonist in tumours while blocking immunosuppressive PD-1/PD-L1 interactions. The bivalent nanobody–STING agonist conjugate stimulated robust antigen-specific T-cell responses and long-lasting immunological memory and conferred enhanced therapeutic efficacy. It was also effective as a neoadjuvant treatment to adoptive T-cell therapy. As a modular approach, hitchhiking STING agonists on serum albumin may serve as a broadly applicable strategy for augmenting the potency of systemically administered cancer immunotherapies.

19 September 2023 in Nanoscale
Verified
Journal Article
Open access
PDF file
HPHayden M. Pagendarm
Hayden M. Pagendarm
PSPayton T. Stone
Payton T. Stone
BKBlaise Russel Kimmel
Blaise Russel Kimmel
JBJessalyn J. Baljon
Jessalyn J. Baljon
MAMina H. Aziz
Mina H. Aziz
JWJohn T. Wilson
John T. Wilson
The clinical translation of many biomolecular therapeutics has been hindered by undesirable pharmacokinetic (PK) properties, inadequate membrane permeability, poor endosomal escape and cytosolic delivery, and/or susceptibility to degradation. Overcoming these challenges merits the development of nanoscale drug carriers (nanocarriers) to improve the delivery of therapeutic cargo. Herein, we implement a flash nanoprecipitation (FNP) approach to produce nanocarriers of diverse vesicular morphologies by using various molecular weight PEG-bl-DEAEMA-co-BMA (PEG-DB) polymers. We demonstrated that FNP can produce uniform (PDI < 0.1) particles after 5 impingements, and that by varying the copolymer hydrophilic mass fraction, FNP enables access to a diverse variety of nanoarchitectures including micelles, unilamellar vesicles (polymersomes), and multi-compartment vesicles (MCVs). We synthesized a library of 2 kDa PEG block copolymers, with DEAEMA-co-BMA second block molecular weights of 3, 6, 12, 15, 20, and 30 kDa. All formulations were both pH responsive, endosomolytic, and capable of loading and cytosolically delivering small negatively charged molecules – albeit to different degrees. Using a B16.F10 melanoma model, we showcased the therapeutic potential of a lead FNP formulated PEG-DB nanocarrier, encapsulating the cyclic dinucleotide (CDN) cGAMP to activate the stimulator of interferon genes (STING) pathway in a therapeutically relevant context. Collectively, these data demonstrate that an FNP process can be used to formulate pH-responsive nanocarriers of diverse morphologies using a PEG-DB polymer system. As FNP is an industrially scalable process, these data address the critical translational challenge of producing PEG-DB nanoparticles at scale. Furthermore, the diverse morphologies produced may specialize in the delivery of distinct biomolecular cargos for other therapeutic applications, implicating the therapeutic potential of this platform in an array of disease applications.

3 May 2024 in Advanced Healthcare Materials
Verified
Journal Article
Open access
CPChristian R. Palmer
Christian R. Palmer
LPLucinda E. Pastora
Lucinda E. Pastora
BKBlaise Russel Kimmel
Blaise Russel Kimmel
HPHayden M. Pagendarm
Hayden M. Pagendarm
AKAlexander J. Kwiatkowski
Alexander J. Kwiatkowski
JWJohn T. Wilson
John T. Wilson
RNA ligands of retinoic acid‐inducible gene I (RIG‐I) are a promising class of oligonucleotide therapeutics with broad potential as antiviral agents, vaccine adjuvants, and cancer immunotherapies. However, their translation has been limited by major drug delivery barriers, including poor cellular uptake, nuclease degradation, and an inability to access the cytosol where RIG‐I is localized. Here this challenge is addressed by engineering nanoparticles that harness covalent conjugation of 5′‐triphospate RNA (3pRNA) to endosome‐destabilizing polymers. Compared to 3pRNA loaded into analogous nanoparticles via electrostatic interactions, it is found that covalent conjugation of 3pRNA improves loading efficiency, enhances immunostimulatory activity, protects against nuclease degradation, and improves serum stability. Additionally, it is found that 3pRNA could be conjugated via either a disulfide or thioether linkage, but that the latter is only permissible if conjugated distal to the 5′‐triphosphate group. Finally, administration of 3pRNA‐polymer conjugates to mice significantly increases type‐I interferon levels relative to analogous carriers that use electrostatic 3pRNA loading. Collectively, these studies have yielded a next‐generation polymeric carrier for in vivo delivery of 3pRNA, while also elucidating new chemical design principles for covalent conjugation of 3pRNA with potential to inform the further development of therapeutics and delivery technologies for pharmacological activation of RIG‐I.

28 August 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
AKAlexander J. Kwiatkowski
Alexander J. Kwiatkowski
JSJacob A. Schulman
Jacob A. Schulman
HPHayden M. Pagendarm
Hayden M. Pagendarm
LPLucinda E. Pastora
Lucinda E. Pastora
JTJohn T. Tossberg
John T. Tossberg
JWJohn T. Wilson
John T. Wilson
Vaccine adjuvants stimulate innate immunity to enhance and shape adaptive immune responses. However, approved adjuvants typically elicit weak CD8+ T cell responses to protein- and peptide-based vaccines, motivating an investigation into the discovery and testing of new adjuvants. Unedited forms of endogenous Alu RNAs are sensed by pattern recognition receptors (PRRs) to trigger sterile inflammation, and therefore we hypothesized that synthetic Alu RNA molecules could be harnessed as vaccine adjuvants. To enhance their intracellular delivery, Alu RNA was copackaged with a model antigen into polymer nanoparticles that promoted endosomal escape of Alu RNA to the cytosol. Using this nanovaccine formulation, we found that Alu RNA activated antigen-presenting cells in vitro and in vaccine-site draining lymph nodes in vivo. Furthermore, we demonstrated that vaccine formulations containing Alu RNA as an adjuvant elicited comparable CD8+ T cell responses to those containing the common but highly heterogeneous RNA adjuvant PolyIC, and that this response protected mice from tumor challenge. Based on this, we further evaluated the antitumor efficacy of nanovaccine formulations containing Alu RNA adjuvants in mice with established tumors, again observing comparable responses to formulations containing PolyIC. Finally, we found that nanovaccines adjuvanted with Alu RNA could improve responses to anti-PD-1 immune checkpoint blockade in tumor-bearing mice. Overall, this study demonstrates that unedited Alu RNA coformulated with antigen in polymer nanoparticles can be harnessed as an effective vaccine adjuvant for stimulating CD8+ T cell responses with antitumor function and may offer a sequence-defined alternative to PolyIC.

30 April 2026 in Biomaterials
Verified
Journal Article
Open access
JSJacob A. Schulman
Jacob A. Schulman
KAKaran Arora
Karan Arora
AKAlexander J. Kwiatkowski
Alexander J. Kwiatkowski
NCNeil C. Chada
Neil C. Chada
JSJulia A. Steele
Julia A. Steele
JWJohn T. Wilson
John T. Wilson
The stimulator of interferon genes (STING) pathway is a promising immuno-oncology target. Despite their potential, STING agonists have yielded underwhelming results in clinical trials due to pharmacological barriers that limit their safety and efficacy. Herein, we describe the design and pre-clinical evaluation of a polymeric dimeric amidobenzimidazole (diABZI) STING agonist delivery platform for cancer immunotherapy. Central to our technology is a stimuli-responsive diABZI-functionalized reversible addition-fragmentation chain transfer (RAFT) polymerization chain transfer agent (CTA) that allows well-defined polymer chains to be grown directly from a single STING agonist. Using a biocompatible poly(N,N'-dimethylacrylamide) polymer as a first-generation scaffold and a disulfide as a clinically relevant linker, we demonstrate our platform liberates a potent diABZI analog under reducing conditions to trigger STING-driven inflammatory gene expression in tumors, thereby stimulating antitumor immunity in multiple murine models and synergizing with α-PD-1 immune checkpoint blockade to eliminate tumors. This work therefore establishes a promising delivery platform for microenvironmental regulation of STING activation with promise as an immunotherapy for cancer.